Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013, which is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has rapidly advanced its drug pipeline with an aim of leading in global competition, focusing on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. And to date, Ascletis has 20+ drug candidates in its R&D pipeline. The most advanced drug candidates include ASC10 (RSV infection), ASC22 (CHB functional cure), ASC40 (acne), ASC40 (recurrent glioblastoma), ASC40 (NASH), ASC41 (NASH) and ASC61 (advanced solid tumors).
Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex / Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.
